DOCS - Ticker AI Digest

Dr. Martens PLC 📰 1
TradingFloor AI GO VIP Login

Digested News

Today's Catalysts (DOCS) 1
DOCS 11:36
Dr. Martens PLC
Block listing Interim Review
AI 0
No items for this category on selected date.
Acquisitions 0
No items for this category on selected date.
Agreement 0
No items for this category on selected date.
Approvals 0
No items for this category on selected date.
Authorisation 0
No items for this category on selected date.
Awards 0
No items for this category on selected date.
BTC 0
No items for this category on selected date.
Blockchain 0
No items for this category on selected date.
Breakthrough 0
No items for this category on selected date.
BuyBack 0
No items for this category on selected date.
Cancellations 0
No items for this category on selected date.
CashOffer 0
No items for this category on selected date.
Collaborate 0
No items for this category on selected date.
ContractWin 0
No items for this category on selected date.
Covid-19 0
No items for this category on selected date.
Deals 0
No items for this category on selected date.
Diamond 0
No items for this category on selected date.
DirectorDealing 1
DOCS 13:14
Dr. Martens PLC
Director/PDMR Shareholding
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
The SIP is an HMRC approved, all-employee scheme under which participating employees are able to <mark style="background-color:yellow">purchase</mark> shares in the Company from monthly salary (Partnership Shares) and receive allocations of free Matching Shares, awarded at a rate of one Matching Share for every one Partnership Share purchased by a participating employee, from the Company.
Discovery 0
No items for this category on selected date.
Exceeded 0
No items for this category on selected date.
FCA 0
No items for this category on selected date.
FDA 0
No items for this category on selected date.
Grants 0
No items for this category on selected date.
InvestmentPlan 0
No items for this category on selected date.
JV 0
No items for this category on selected date.
Launch 0
No items for this category on selected date.
Litigation 0
No items for this category on selected date.
NewContract 0
No items for this category on selected date.
Offers 0
No items for this category on selected date.
Offtake 0
No items for this category on selected date.
Orders 0
No items for this category on selected date.
Partner 0
No items for this category on selected date.
Patents 0
No items for this category on selected date.
Placing 0
No items for this category on selected date.
Positive 0
No items for this category on selected date.
Proposals 0
No items for this category on selected date.
Reports 0
No items for this category on selected date.
Results 1
DOCS 06:01
Dr. Martens PLC
H1 FY26 Results
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary of Dr. Martens PLC H1 FY26 Results (26 weeks ended 28 September 2025)**
**Financial Highlights**
**Revenue** £322.0 million, up 0.8% on a constant currency (CC) basis, with full-price direct-to-consumer (DTC) revenue growing 6%, reflecting a focus on improving revenue quality.
**Gross Margin** Improved by 130 basis points to 65.3%, driven by full-price performance and cost management.
**Adjusted EBIT** £3.1 million, significantly improved from a £3.0 million loss in H1 FY25, despite a high single-digit £m headwind from tariffs.
**Adjusted PBT** Loss of £9.2 million, compared to a £16.6 million loss in H1 FY25.
**Net Debt** Reduced to £154.3 million (excluding leases), down from £186.8 million in H1 FY25.
**Interim Dividend** 0.85p per share, in line with policy.
**Strategic Progress**
**Consumer-First Strategy** Shifted from a channel-first to a consumer-first approach, with a 33% increase in shoe volumes and successful launches of new products like the Zebzag Laceless boot and 1460 Rain boot.
**Full-Price Focus** Full-price DTC revenue grew 6%, with a 5-point improvement in full-price mix, reducing reliance on clearance sales.
**Product Innovation** Launched new products to drive purchase occasions, including the Zebzag Laceless boot and 1460 Rain boot, expanding into new footwear segments.
**Market Expansion** Strengthened distribution partnerships in Latin America, Italy, UAE, and the Philippines, and deepened relationships with key wholesale customers.
**Operational Efficiency** Progress in simplifying operations through initiatives like the Customer Data Platform, Supply and Demand Planning system, and Global Technology Centre.
**Regional Performance**
**Americas:** Revenue up 6% CCled by strong full-price DTC growth.
**EMEA** Revenue down 3% CC, with subdued DTC performance due to a promotional environment.
**APAC** Revenue up 2% CC, with strength in South Korea and steady performance in Japan.
**Current Trading and Outlook**
Trading in line with expectations, with FY26 adjusted PBT consensus range of £53-60 million (excluding tariff impact).
Tariffs represent a high single-digit £m headwind for FY26, with roughly half expected to be mitigated through cost control and pricing adjustments.
Currency impact of £10m headwind to revenue and £2m benefit to adjusted PBT based on current spot rates.
**Management Commentary**
CEO Ije Nwokorie emphasized progress in executing the new strategy, with green shoots across growth levers, despite a volatile market. The focus remains on execution and setting the business up for long-term growth.
**Key Metrics**
Pairs sold: 4.7 millionup 1.4%.
Stores: 244up from 238.
DTC mix: 55.7%slightly down from 56.4%.
**Conclusion**
Dr. Martens PLC is making steady progress in its strategic transformation, with improved financial performance and operational efficiency. Despite market challenges, the company remains confident in its plans for the year and beyond, focusing on sustainable, profitable growth.
Significant 0
No items for this category on selected date.
Speculation 0
No items for this category on selected date.
Strategic 0
No items for this category on selected date.
Suspension 0
No items for this category on selected date.
TR1 1
DOCS 06:01
Dr. Martens PLC
Holding(s) in Company
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
Takeover 0
No items for this category on selected date.
Understanding 0
No items for this category on selected date.
Updates 0
No items for this category on selected date.
Vaccine 0
No items for this category on selected date.
Wins 0
No items for this category on selected date.
Worth 0
No items for this category on selected date.
All Market News (Last 30 Days) 5
DOCS 11:36
Dr. Martens PLC
Block listing Interim Review
DOCS 10:59
Dr. Martens PLC
Total Voting Rights
DOCS 06:01
Dr. Martens PLC
Holding(s) in Company
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
DOCS 06:01
Dr. Martens PLC
H1 FY26 Results
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary of Dr. Martens PLC H1 FY26 Results (26 weeks ended 28 September 2025)**
**Financial Highlights**
**Revenue** £322.0 million, up 0.8% on a constant currency (CC) basis, with full-price direct-to-consumer (DTC) revenue growing 6%, reflecting a focus on improving revenue quality.
**Gross Margin** Improved by 130 basis points to 65.3%, driven by full-price performance and cost management.
**Adjusted EBIT** £3.1 million, significantly improved from a £3.0 million loss in H1 FY25, despite a high single-digit £m headwind from tariffs.
**Adjusted PBT** Loss of £9.2 million, compared to a £16.6 million loss in H1 FY25.
**Net Debt** Reduced to £154.3 million (excluding leases), down from £186.8 million in H1 FY25.
**Interim Dividend** 0.85p per share, in line with policy.
**Strategic Progress**
**Consumer-First Strategy** Shifted from a channel-first to a consumer-first approach, with a 33% increase in shoe volumes and successful launches of new products like the Zebzag Laceless boot and 1460 Rain boot.
**Full-Price Focus** Full-price DTC revenue grew 6%, with a 5-point improvement in full-price mix, reducing reliance on clearance sales.
**Product Innovation** Launched new products to drive purchase occasions, including the Zebzag Laceless boot and 1460 Rain boot, expanding into new footwear segments.
**Market Expansion** Strengthened distribution partnerships in Latin America, Italy, UAE, and the Philippines, and deepened relationships with key wholesale customers.
**Operational Efficiency** Progress in simplifying operations through initiatives like the Customer Data Platform, Supply and Demand Planning system, and Global Technology Centre.
**Regional Performance**
**Americas:** Revenue up 6% CCled by strong full-price DTC growth.
**EMEA** Revenue down 3% CC, with subdued DTC performance due to a promotional environment.
**APAC** Revenue up 2% CC, with strength in South Korea and steady performance in Japan.
**Current Trading and Outlook**
Trading in line with expectations, with FY26 adjusted PBT consensus range of £53-60 million (excluding tariff impact).
Tariffs represent a high single-digit £m headwind for FY26, with roughly half expected to be mitigated through cost control and pricing adjustments.
Currency impact of £10m headwind to revenue and £2m benefit to adjusted PBT based on current spot rates.
**Management Commentary**
CEO Ije Nwokorie emphasized progress in executing the new strategy, with green shoots across growth levers, despite a volatile market. The focus remains on execution and setting the business up for long-term growth.
**Key Metrics**
Pairs sold: 4.7 millionup 1.4%.
Stores: 244up from 238.
DTC mix: 55.7%slightly down from 56.4%.
**Conclusion**
Dr. Martens PLC is making steady progress in its strategic transformation, with improved financial performance and operational efficiency. Despite market challenges, the company remains confident in its plans for the year and beyond, focusing on sustainable, profitable growth.
DOCS 13:14
Dr. Martens PLC
Director/PDMR Shareholding
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
The SIP is an HMRC approved, all-employee scheme under which participating employees are able to <mark style="background-color:yellow">purchase</mark> shares in the Company from monthly salary (Partnership Shares) and receive allocations of free Matching Shares, awarded at a rate of one Matching Share for every one Partnership Share purchased by a participating employee, from the Company.

AI Crunch

Single-Ticker AI Crunch
DOCS signal theatre built from scored market catalysts, automated AI forecasts, and live trigger logic.

This is the ticker-specific AI Crunch desk for Dr. Martens PLC. It compresses bullish and bearish catalyst scoring, best and worst AI forecast paths, and automated buy or sell trigger logic into one cockpit so users can judge conviction without hopping across screens.

Subscription Required Bullish vs Bearish Scoring AI Forecast Stack Buy / Sell Trigger Engine Catalyst Ledger
Create Account Member Login
Subscriber Unlock
Subscribe to unlock the full DOCS AI Crunch cockpit.

Subscription turns this tab into a live signal desk with bullish vs bearish machine scoring, AI forecast stack comparisons, buy and sell trigger logic, and the full catalyst ledger behind every scored catalyst row.

  • AI-scored market headlines with sentiment buckets and buzzword breakdowns.
  • Forecast leaders ranked by projected gain against current market price.
  • Advanced technical scans, AI forecast stacks, and predictive MACD inside the live stock terminal charts.
  • Single-ticker AI Crunch desks with buy or sell trigger logic and full catalyst ledgers.
  • Scored earnings shock board with predicted direction, sector pulse and catalyst narrative.
  • Fast market scan built for event-driven trading, not passive dashboards.
Subscribe to unlock the ticker-specific signal stack, sentiment gauges, forecast stage, and the full catalyst ledger for DOCS on 2025-12-01.

Fundamentals Matrix

Overall Fundamentals
Signal: Pending
Capital Strength
Signal: Pending
Float Liquidity
Signal: Pending
Short Pressure
Signal: Pending
Target Setup
Signal: Pending
Market Profile
Signal: Pending
Market Cap
638046848
Enterprise Value
3005455882
Public Float
53.78
Broker Target
103.5
Shares Out
966737603
Long Interest
86
Short Interest
14
Exchange
LSE
Currency Code
GBX
ISIN
GB00BL6NGV24
Market
LSE - MAIN MARKET
Sector
Personal Goods
Float / Shares Ratio
-
Short vs Long Delta
-
EV / Market Cap
-

Financials Matrix

Overall Stability
Signal: Pending
Profitability
Signal: Pending
Debt & Cash
Signal: Pending
Valuation Risk
Signal: Pending
Forward Expectation
Signal: Pending
Dividend Safety
Signal: Pending
Divi Rate
0.03
Ex Divi
2026-03-05
Earnings Date
2025-11-20
Net Debt
248200000.0
Cash
155900000.0
EPS
0.02
Net Income
4500000.0
Revenue
787600000.0
Enterprise Value
3005455882
Trailing PE
33
Forward PE
0.254
Price Sales TTM
0.7943
Price Book MRQ
1.9153
EV Revenue
1.1869
EV EBITDA
7.4537

Capital Radar

Capital Regime
—
Building signal blend...
Smart Money Tilt
—
Public vs institutions
Target Conviction
—
Broker coverage pulse
Insider Pressure
—
Director + TR1 flow
Last Held Position
-
Public Hands
-
Institutions
20.426
Institutions As Of
2026-03-20
Avg Broker Target
-
Upside Vs Price
-
Purchase Director Dealing
25
Sale Director Dealing
2
Purchase TR1
5
Sale TR1
1
Broker Coverage Rows
0
Institution Holders Tracked
2
Public Vs Institutional Ownership (3D)
Top Institution Holders (Latest Per Holder)
Director Dealing Sentiment Flow
Broker Target Bias
Signal: Pending
Capital Momentum Matrix
Broker Targets Vs Price
Aggregated Institution Weight By Holder

Short Data - Last 30 Days

Nexus Pulse Engine

Overall Buy/Sell/Hold
Signal: Pending
Technical Composite
Signal: Pending
Financial Composite
Signal: Pending
Fundamental Composite
Signal: Pending
Short Pressure
Signal: Pending
Momentum Bias
Signal: Pending

Volatility Lab

ATR(14)
Realized Vol (20d)
Volume Spike Z

AI Charts

Today's Catalysts

1 live catalyst just hit DOCS.

The headlines landing in Digested News are now framed here as today's catalyst tape. Scroll the tab rail to Digested News or jump there instantly below.
Live Tape Data 2025-12-01 AI Charts Landing View
Scroll the tab rail to Digested News any time, or use the jump button to land straight on today's tape.
1 Today
Catalyst Pulse
Dr. Martens PLC has fresh news flow feeding the chart narrative.
11:36 Today's Catalyst Block listing Interim Review
AI Charts Studio
DOCS Price History
Live structure, automated forecasts, technical overlays and catalyst beacons in one chart workspace.
30 Day View Window 30D Data 2025-12-01 Open Preview Studio Brief
Chart Intelligence Suite
Swipe the timeframe, call the overlays, and keep the AI signal stack fused into one chart cockpit.
The mobile chart console is now framed as one connected surface so forecasting, structure, catalyst beacons and chart tools all sit inside the price workspace.

Automated signalling scans momentum shifts, crossovers and volatility breaks in real time. Automated AI forecasts map best, average and worst simulation paths forward, predictive MACD extends the momentum story, and catalyst beacons pin market-moving headlines directly onto price action so users can connect news, signals and structure without leaving the chart.

Automated Signalling Automated AI Forecasts Predictive MACD Catalyst Beacons Live Price Structure
TradingFloor AI Member Login
Indicators0
Technicals0
AI Forecast -6.12%
RSI Gauge
Price Change
AI Forecast